Skip to main content

Clinical Trials Using Durvalumab

Review the clinical trials studying durvalumab on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 26-50 of 83

Ceralasertib with or without Olaparib or Durvalumab in Treating Patients with Locally Advanced or Metastatic Solid Tumors
Status: Active
Location: 4 locations
Tremelimumab and Durvalumab with and without Selective Internal Yttrium-90 Radioembolization before Surgery for the Treatment of Resectable Hepatocellular Carcinoma
Status: Active
Location: 4 locations
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
Status: Active
Location: 3 locations
A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)
Status: Active
Location: 3 locations
Celecoxib, Durvalaumab and Tremellimumab for the Treatment of Patients with Advanced or Metastatic Liver Cancer
Status: Active
Location: 4 locations
Trastuzumab Deruxtecan and Durvalumab Before Surgery for the Treatment of Patients with Stage III, HER2-Expressing Inflammatory Breast Cancer
Status: Active
Location: 3 locations
Carboplatin or Cisplatin, Etoposide, and Durvalumab with Hypofractionated Ablative Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, DARES Study
Status: Active
Location: 3 locations
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
Status: Active
Location: 3 locations
Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder
Status: Active
Location: 5 locations
Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases
Status: Active
Location: 3 locations
Quick Start Durvalumab Following Chemoradiation for the Treatment of Stage II or III Non-small Cell Lung Cancer
Status: Active
Location: 2 locations
Hypofractionated Radiotherapy Followed by Durvalumab with or without Tremelimumab for the Treatment of Liver Cancer
Status: Active
Location: 2 locations
Durvalumab Plus Monalizumab for the Treatment of Non-muscle Invasive Bladder Cancer in Patients Unresponsive to Bacillus Calmette-Guerin or with Exposed Cancer in Situ, ENHANCE Trial
Status: Active
Location: 2 locations
Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC after Chemoradiation and Anti-PD-L1 Therapy
Status: Active
Location: 2 locations
Futibatinib in Combination with Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients who are Ineligible for Cisplatin-based Therapy
Status: Active
Location: 2 locations
Restorative Microbiota Therapy in Combination with Durvalumab, Tremelimumab, and Chemotherapy for the Treatment of Stage IIIB-IV Non-small Cell Lung Cancer
Status: Active
Location: 2 locations
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
Status: Active
Location: 2 locations
Zanzalintinib with Durvalumab plus Tremelimumab for the Treatment of Patients with Unresectable Hepatocellular Carcinoma, The ZENOBIA Trial
Status: Active
Location: 2 locations
Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC
Status: Active
Location: 2 locations
Papaverine in Combination with Chemoradiation for the Treatment of Stage II, III, or IV Non-small Cell Lung Cancer
Status: Active
Location: 2 locations
Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
Status: Active
Location: Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York
Comparing Length of Treatment with Immunotherapy in Patients with Advanced Solid Tumors
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Durvalumab for the Treatment of Patients with Stage IA2-III Non-small Cell Lung Cancer who Have Minimal Residual Disease
Status: Active
Location: Stanford Cancer Institute Palo Alto, Palo Alto, California
Personalized Treatment following Chemoradiotherapy and Immunotherapy for the Treatment of Stage III Non-small Cell Lung Cancer
Status: Active
Location: Stanford Cancer Institute Palo Alto, Palo Alto, California
Immunotherapy with or without Radiation Therapy for the Treatment of Patients with Advanced Unresectable Intrahepatic Cholangiocarcinoma, a HYPERION CCA Trial
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas